ENTA – Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc.ENTA
$12.60Name : Enanta Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $363,546,848.00
EPSttm : -4.32
Enanta Pharmaceuticals, Inc.
$12.60
4.48%$0.54Float Short %
9.98
Margin Of Safety %
Put/Call OI Ratio
0.89
EPS Next Q Diff
-0.17
EPS Last/This Y
1.76
EPS This/Next Y
0.44
Price
12.03
Target Price
18.88
Analyst Recom
1.38
Performance Q
47.61
Relative Volume
0.4
Beta
0.98
Ticker: ENTA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | ENTA | 11.11 | 0.48 | 0.16 | 1820 |
| 2025-10-21 | ENTA | 11.04 | 0.45 | 0.09 | 1967 |
| 2025-10-22 | ENTA | 10.43 | 0.45 | 54.00 | 1986 |
| 2025-10-23 | ENTA | 10.66 | 0.75 | 0.14 | 2408 |
| 2025-10-24 | ENTA | 10.5 | 0.73 | 2.00 | 2399 |
| 2025-10-27 | ENTA | 10.48 | 0.73 | 8.00 | 2400 |
| 2025-10-28 | ENTA | 10.47 | 0.75 | 0.85 | 2434 |
| 2025-10-29 | ENTA | 10.66 | 0.76 | 2.00 | 2451 |
| 2025-10-30 | ENTA | 10.87 | 0.77 | 0.00 | 2456 |
| 2025-10-31 | ENTA | 10.95 | 0.76 | 20.00 | 2477 |
| 2025-11-03 | ENTA | 10.82 | 0.77 | 75.00 | 2496 |
| 2025-11-04 | ENTA | 10.84 | 0.77 | 75.00 | 2496 |
| 2025-11-05 | ENTA | 10.91 | 0.77 | 75.00 | 2496 |
| 2025-11-06 | ENTA | 10.78 | 0.77 | 75.00 | 2496 |
| 2025-11-07 | ENTA | 10.98 | 0.88 | 0.06 | 2647 |
| 2025-11-10 | ENTA | 11.5 | 0.89 | 0.00 | 2631 |
| 2025-11-11 | ENTA | 12.02 | 0.89 | 0.00 | 2631 |
| 2025-11-12 | ENTA | 11.92 | 0.87 | 0.10 | 2666 |
| 2025-11-13 | ENTA | 11.71 | 0.86 | 0.00 | 2675 |
| 2025-11-14 | ENTA | 12.05 | 0.89 | 0.06 | 2624 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | ENTA | 11.11 | 25.4 | - | -3.72 |
| 2025-10-21 | ENTA | 10.97 | 25.4 | - | -3.72 |
| 2025-10-22 | ENTA | 10.49 | 25.4 | - | -3.72 |
| 2025-10-23 | ENTA | 10.65 | 25.4 | - | -3.72 |
| 2025-10-24 | ENTA | 10.49 | 25.4 | - | -3.72 |
| 2025-10-27 | ENTA | 10.49 | 25.4 | - | -3.72 |
| 2025-10-28 | ENTA | 10.47 | 25.4 | - | -3.72 |
| 2025-10-29 | ENTA | 10.63 | 25.4 | - | -3.72 |
| 2025-10-30 | ENTA | 10.86 | 25.4 | - | -3.72 |
| 2025-10-31 | ENTA | 10.96 | 25.4 | - | -3.72 |
| 2025-11-03 | ENTA | 10.81 | 25.4 | - | -3.72 |
| 2025-11-04 | ENTA | 10.82 | 25.4 | - | -3.72 |
| 2025-11-05 | ENTA | 10.90 | 25.4 | - | -3.72 |
| 2025-11-06 | ENTA | 10.78 | 25.4 | - | -3.72 |
| 2025-11-07 | ENTA | 10.99 | 25.4 | - | -3.72 |
| 2025-11-10 | ENTA | 11.51 | 25.4 | - | -3.72 |
| 2025-11-11 | ENTA | 12.04 | 25.4 | - | -3.72 |
| 2025-11-12 | ENTA | 11.93 | 25.4 | - | -3.72 |
| 2025-11-13 | ENTA | 11.69 | 25.4 | - | -3.72 |
| 2025-11-14 | ENTA | 12.03 | 25.4 | - | -3.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | ENTA | 0.00 | -1.66 | 12.43 |
| 2025-10-21 | ENTA | 0.00 | -1.66 | 12.43 |
| 2025-10-22 | ENTA | 0.00 | -1.66 | 12.43 |
| 2025-10-23 | ENTA | 0.00 | -1.66 | 12.43 |
| 2025-10-24 | ENTA | 0.00 | -1.66 | 12.43 |
| 2025-10-27 | ENTA | 0.00 | -1.16 | 10.44 |
| 2025-10-28 | ENTA | 0.00 | -1.16 | 10.44 |
| 2025-10-29 | ENTA | 0.00 | -1.16 | 10.44 |
| 2025-10-30 | ENTA | 0.00 | -1.16 | 10.44 |
| 2025-10-31 | ENTA | 0.00 | -1.16 | 10.44 |
| 2025-11-03 | ENTA | 0.00 | -1.14 | 10.44 |
| 2025-11-04 | ENTA | 0.00 | -1.14 | 10.44 |
| 2025-11-05 | ENTA | 0.00 | -1.14 | 10.44 |
| 2025-11-06 | ENTA | 0.00 | -1.14 | 10.44 |
| 2025-11-07 | ENTA | 0.00 | -1.14 | 10.44 |
| 2025-11-10 | ENTA | 0.00 | -1.49 | 10.44 |
| 2025-11-11 | ENTA | 0.00 | -1.49 | 10.44 |
| 2025-11-12 | ENTA | 0.00 | -1.49 | 10.14 |
| 2025-11-13 | ENTA | 0.00 | -1.49 | 10.14 |
| 2025-11-14 | ENTA | 0.00 | -1.49 | 9.98 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.85
Avg. EPS Est. Current Quarter
-1.01
Avg. EPS Est. Next Quarter
-1.02
Insider Transactions
Institutional Transactions
-1.49
Beta
0.98
Average Sales Estimate Current Quarter
15
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
20
Growth Score
26
Sentiment Score
94
Actual DrawDown %
88.2
Max Drawdown 5-Year %
-95.6
Target Price
18.88
P/E
Forward P/E
PEG
P/S
5.37
P/B
3.25
P/Free Cash Flow
EPS
-4.32
Average EPS Est. Cur. Y
-3.72
EPS Next Y. (Est.)
-3.27
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-141.98
Relative Volume
0.4
Return on Equity vs Sector %
-142.9
Return on Equity vs Industry %
-128.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.5
EBIT Estimation
Enanta Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 131
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
stock quote shares ENTA – Enanta Pharmaceuticals Inc Stock Price stock today
news today ENTA – Enanta Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ENTA – Enanta Pharmaceuticals Inc yahoo finance google finance
stock history ENTA – Enanta Pharmaceuticals Inc invest stock market
stock prices ENTA premarket after hours
ticker ENTA fair value insiders trading